_____________________
                                                   |    OMB APPROVAL     |
                                                   |_____________________|
                                                   |OMB NUMBER: 	 |
                    UNITED STATES                  |EXPIRES:             |
         SECURITIES AND EXCHANGE COMMISSION        |   JUNE 30, 2012	 |
               Washington, D.C.  20549             |ESTIMATED AVERAGE    |
                                                   |BURDEN HOURS         |
                                                   |PER RESPONSE ...11	 |
                 SCHEDULE 13G                       _____________________|



                    Under the Securities Exchange Act of 1934
                             (Amendment No. _ )*


                     	  SYNTHETIC BIOLOGICS INC (SYN)
                  ---------------------------------------------
                                (Name of Issuer)


                                  Common Stock
                -------------------------------------------------
                         (Title of Class of Securities)


                             	   87164U102
                ----------------------------------------------------
                                 (CUSIP Number)


                                December 31, 2016
 ------------------------------------------------------------------------------
             (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

     [X]  Rule 13d-1(b)

     [ ]  Rule 13d-1(c)

     [ ]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to
the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).


------------------------------------------------------------------------------
CUSIP No.  87164U102			SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Investment Group, L.P.

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                12,437,917
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        12,437,917
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

           12,437,917
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           9.9%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           IA
------------------------------------------------------------------------------

*The reporting persons are the beneficial owners of 4,586,592 shares of Common
Stock of the Issuer and hold a warrant under which they may purchase up to
7,851,235 shares of Common Stock as of December 31, 2016, which constitutes
approximately 9.9% of the Issuer's outstanding Common Stock shares. The
percentage calculation assumes that there are currently 116,652,351 outstanding
shares of Common Stock of the Issuer, based on the Issuer's Form 10-Q as filed
with the Securities and Exchange Commission on November 1, 2016 and a
subsequent issuance of 25,000,000 shares as reported in a prospectus supplement
filed pursuant to Rule 424(b)(5) on November 15, 2016.

------------------------------------------------------------------------------
CUSIP No.  87164U102			SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Fund GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                12,437,917
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        12,437,917
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          12,437,917
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           9.9%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           OO
------------------------------------------------------------------------------


*The reporting persons are the beneficial owners of 4,586,592 shares of Common
Stock of the Issuer and hold a warrant under which they may purchase up to
7,851,235 shares of Common Stock as of December 31, 2016, which constitutes
approximately 9.9% of the Issuer's outstanding Common Stock shares. The
percentage calculation assumes that there are currently 116,652,351 outstanding
shares of Common Stock of the Issuer, based on the Issuer's Form 10-Q as filed
with the Securities and Exchange Commission on November 1, 2016 and a
subsequent issuance of 25,000,000 shares as reported in a prospectus supplement
filed pursuant to Rule 424(b)(5) on November 15, 2016.

------------------------------------------------------------------------------
CUSIP No.  87164U102			SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

          Alyeska Fund 2 GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ]
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                              	12,437,917
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        12,437,917
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          12,437,917
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
           9.9%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
           OO
------------------------------------------------------------------------------


*The reporting persons are the beneficial owners of 4,586,592 shares of Common
Stock of the Issuer and hold a warrant under which they may purchase up to
7,851,235 shares of Common Stock as of December 31, 2016, which constitutes
approximately 9.9% of the Issuer's outstanding Common Stock shares. The
percentage calculation assumes that there are currently 116,652,351 outstanding
shares of Common Stock of the Issuer, based on the Issuer's Form 10-Q as filed
with the Securities and Exchange Commission on November 1, 2016 and a
subsequent issuance of 25,000,000 shares as reported in a prospectus supplement
filed pursuant to Rule 424(b)(5) on November 15, 2016.

-------------------------------------------------------------------------------
CUSIP No. 87164U102            	 SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
	  Anand Parekh

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions):
                                                           (a) [ ]
                                                           (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
          United States of America
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                12,437,917
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER
                                        12,437,917
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

   	 12,437,917
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
          9.9%*
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions)
          IN
------------------------------------------------------------------------------


*The reporting persons are the beneficial owners of 4,586,592 shares of Common
Stock of the Issuer and hold a warrant under which they may purchase up to
7,851,235 shares of Common Stock as of December 31, 2016, which constitutes
approximately 9.9% of the Issuer's outstanding Common Stock shares. The
percentage calculation assumes that there are currently 116,652,351 outstanding
shares of Common Stock of the Issuer, based on the Issuer's Form 10-Q as filed
with the Securities and Exchange Commission on November 1, 2016 and a
subsequent issuance of 25,000,000 shares as reported in a prospectus supplement
filed pursuant to Rule 424(b)(5) on November 15, 2016.


CUSIP NO.  87164U102             SCHEDULE 13G


Item 1(a).      Name of Issuer:
		SYNTHETIC BIOLOGICS INC



Item 1(b).      Address of Issuer's Principal Executive Offices:
                9605 Medical Center Drive, Suite 270
		Rockville, MD 20850



Item 2(a).      Name of Persons Filing:

	(i)	Alyeska Investment Group, L.P.

	(ii)	Alyeska Fund GP, LLC

	(iii)	Alyeska Fund 2 GP, LLC

	(iv)	Anand Parekh




Item 2(b).      Address of Principal Business Office or, if None, Residence:


	(i)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601


	(ii)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601

	(iii)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601

	(iv)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601



Item 2(c).      Citizenship:

		(i)  	Alyeska Investment Group, L.P.- Delaware

		(ii) 	Alyeska Fund GP, LLC- Delaware

		(iii) 	Alyeska Fund 2 GP, LLC- Delaware

		(iv) 	Anand Parekh- United States of America





Item 2(d).       Title of Class of Securities:
		 Common Stock


Item 2(e).      CUSIP Number:
		87164U102



Item 3.          If This Statement is Filed Pursuant to Sections 240.13d-1(b)
                 or 240.13d-2(b), Check Whether the Person Filing is a:

(a) Alyeska Investment Group, L.P., a limited partnership organized under the
laws of the State of Delaware, is a registered investment adviser under Section
203 of the Investment Advisers Act of 1940, as amended, and is reporting in
accordance with 240.13d-1(b)(1)(ii)(E).

(b) Alyeska Fund GP, LLC, a limited liability company organized under the laws
of the State of Delaware, serves as the General Partner and control person of
Alyeska Master Fund, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).

(c) Alyeska Fund 2 GP, LLC, a limited liability company organized under the laws
 of the State of Delaware, serves as the General Partner and control person of
Alyeska Master Fund 2, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).

(d) Anand Parekh is the Chief Executive Officer and control person of Alyeska
Investment Group, L.P., and is reporting in accordance with
240.13d-1(b)(1)(ii)(G).



Item 4.  Ownership.

Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer identified
in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover
	pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached
	hereto

    (c)	Number of shares as to which the person has: Please refer to items
	5-8 of the cover pages attached hereto

The reporting persons are the beneficial owners of 4,586,592 shares of Common
Stock of the Issuer and hold a warrant to purchase 10,000,000 shares of the
Issuer's Common Stock ("Warrant").  However, the Warrant contains a provision
limiting its exercise to only such number of shares that would constitute 9.99%
of the total number of Common Stock of the Issuer then outstanding when
aggregated with all shares beneficially owned by the holder and its affiliates
and any other person or entities with which such holder would constitute a
Section 13(d) "group."  Accordingly, as of December 31, 2016 the reporting
persons may only purchase up to 7,851,235 shares of Common Stock under the
Warrant, and as such, are reporting beneficial ownership of only such number of
shares.  The percentage calculation assumes that there are currently 116,652,351
outstanding shares of Common Stock of the Issuer, based on the Issuer's
Form 10-Q as filed with the Securities and Exchange Commission on
November 1, 2016 and a subsequent issuance of 25,000,000 shares as reported in
a prospectus supplement filed pursuant to Rule 424(b)(5) on November 15, 2016.


Item 5.  Ownership of Five Percent or Less of a Class.
	 Not Applicable



Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
	 Not Applicable



Item 7.  Identification and Classification of the Subsidiary Which Acquired
         the Security Being Reported on By the Parent Holding Company or
         Controlling Person.
	 Not Applicable



Item 8.  Identification and Classification of Members of the Group.
	 Not Apllicable



Item 9.  Notice of Dissolution of Group
	 Not Applicable



Item 10. Certification

         By signing below I certify that, to the best of my knowledge and
         belief, the securities referred to above were not acquired and are not
         held for the purpose of or with the effect of changing or influencing
         the control of the issuer of the securities and were not acquired and
         are not held in connection with or as a participant in any transaction
         having that purpose or effect.


CUSIP NO.  87164U102           	  SCHEDULE 13G


                                   SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.


Dated: February 14, 2017


Alyeska Investment Group, L.P.

By: /s/ Jason Bragg
    -------------------------------
    Name: Jason Bragg
    Title: Chief Financial Officer and Chief Compliance Officer


Alyeska Fund GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer and Chief Compliance Officer


Alyeska Fund 2 GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer and Chief Compliance Officer


Anand Parekh

By: /s/ Anand Parekh
    -------------------------------
    Name: Anand Parekh
    Individually




CUSIP NO. 87164U102            	SCHEDULE 13G


                                Exhibit A
				Agreement


The undersigned agree that the statement to which this exhibit is appended is
filed on behalf of each of them.

Dated:  February 14, 2017


Alyeska Investment Group, L.P.

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer and Chief Compliance Officer


Alyeska Fund GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer and Chief Compliance Officer


Alyeska Fund 2 GP, LLC

By: /s/ Jason Bragg
    -------------------------------
    Name:  Jason Bragg
    Title: Chief Financial Officer and Chief Compliance Officer


Anand Parekh

By: /s/ Anand Parekh
    -------------------------------
    Name: Anand Parekh
    Individually